Drug Profile

CL S001 - Cellusion

Alternative Names: CLS 001 - Cellusion

Latest Information Update: 28 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellusion
Class Eye disorder therapies; Induced pluripotent stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Corneal disorders
New Molecular Entity No

Highest Development Phases

No development reported Corneal disorders

Most Recent Events

28 Aug 2024 No recent reports of development identified for phase-I development in Corneal-disorders(In the elderly, In adults) in Japan (Intraocular, Injection)
22 Dec 2023 CL S001 - Cellusion receives Orphan Drug status for Corneal disorders in USA
27 Mar 2023 Efficacy and adverse events data from a phase I trial in Corneal disorders released by Cellusion

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com